Rochester, NY 6/26/2009 3:36:31 AM
After Hours - SQNM - Sequenom Not Required To Make Payments to Beckman or Orchid - Sourced WhisperFromWallStreet.com
Sequenom, Inc.
After Hours - SQNM - Sequenom Not Required To Make Payments to Beckman or Orchid - Sourced WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert. We have sent out 40 alerts so far in 2009 with an average price gain of over 80%. Please join risk free and see for yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Sequenom, Inc.,SQNM
After Hours: 4.01 Down 0.06 (1.50%) 4:13PM ET
Sequenom discloses that court ruled it is not required to make any payments to Beckman Coulter or Orchid Cellmark Co discloses that on June 22, 2009, following a Markman (patent claim construction) hearing held on June 11, 2009, the parties in Beckman Coulter (BEC) and Orchid Cellmark (ORCH) v. Sequenom filed a stipulation of dismissal in the United States District Court for the Southern District of California in which the parties stipulated that (i) the patent infringement action brought by Beckman Coulter and Orchid Cellmark against us was dismissed with prejudice, (ii) the counter claims brought by us against Beckman Coulter and Orchid Cellmark were dismissed without prejudice, and (iii) each party to the lawsuit agreed to bear its own attorneys' fees and costs. "We are not required to make any payments to Beckman Coulter or Orchid Cellmark nor are we required to take a license to the patents, and, as such, the conclusion of this litigation has no material adverse impact on our business, financial condition, or results of operation."
Last Trade: 2.27
Day's Range: 1.63 - 2.47
52wk Range: 0.60 - 10.58
Volume: 18,740,983
ABOUT
Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations..
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
